



Covid-19: Medicines Criticality Groups

Department of Health, Miesian Plaza,

Friday, 13th March 2020

No	Action Detail	Owner	By When	Update	Status
1	Look at medicines used in Irish hospitals that may potentially be used to treat Covid 19, to treat secondary infections and as supportive treatments	AMRIC & AHDMP (HSE)	10/03/20	HPRA in communication with ADHMP	
2	MAHs to be contacted re availability of medicines referred to above	AHDMP		A few MAHs some had concerns	
3	Discussion with HBS re central procurement of medicines to treat Covid 19, to treat secondary infections and as supportive treatments. Consideration as to how private hospitals are to be included.	Acute Strategy & Planning & ADHMP (HSE)	10/03/20	DoH had query re. policy elements of eligibility	
4	HSE Modelling data to be shared with group when available	Department of Health	10/03/20	To follow up as still have no sight on data	
5	PCRS to contact relevant MAH re available supply of hydroxychloroquine	PCRS (HSE)	13/03/20		
6	PCRS to issue communication re use of hydroxychloroquine	PCRS (HSE)	13/03/20	PCRS in process of issuing comms	
7	Contact MAH re availability Oseltamivir	AHDMP (HSE)	13/03/20	MAH has good stocks and will seek to move more to Ireland	
8	HPRA to develop template to capture the order of review of medicines, details of medicines to be considered and companies contacted and a summary of those contacts	HPRA	13/03/20		
9	HPRA to provide update on status of questionnaire to MAHs	HPRA	13/03/20	HPRA hope to have full	



				questionnaire by EOD Monday	
10	DoH to issue communication from group chair to relevant stakeholders	Department of Health	13/03/20	Completed	
11	AHDMP to contact supplier re TPN	AHDMP (HSE)	13/03/20	stock status green	
12	AHDMP send guidance for hospitals document to Prof. Bergin	AHDMP (HSE)	13/03/20		
13	Group to review impact of comms as regards the perceived pull on supply chains	DoH / HPRA	Ongoing	General guidance is usual supply +10%	
14	PCRS to update Group on mechanism to ensure sufficient stock of hydroxychloroquine to treat patients already undergoing treatment with hydroxychloroquine (not for antiviral purposes) by limiting de novo patients on for antiviral purposes	PCRS (HSE)	18/03/20		
15	Issue for discussion: National Cancer Control Programme (NCCP) query re. tocilizumab, hydroxychloroquine and blood products	For discussion during call	18/03/20		